ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Pfizer, LG Chem and Merck side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Pfizer×LG Chem×Merck×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

PfizerLG ChemMerck
studies on the registry4,0731842,453
open to participants now14710145
phase 3 studies under way993112
reach primary completion within a year92260
programswith a study of their own in two years91+9 named only1085

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phasePfizerLG ChemMerck
Phase 1

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%

LG Chem: 2 of its 10 programs at phase 1

  1. Reference Drug (Eutropin, 4 IU/vial)phase 1
  2. Test Drug (Eutropin Catridge, 48IU/Cartridge)phase 1
20%

Merck: 27 of its 85 programs at phase 1

  1. MK4646phase 1
  2. F-2phase 1
  3. MK-7602phase 1
  4. V118Cphase 1
  5. MK-4716phase 1

and 22 more — sign in to see them all

32%
Phase 2

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%

LG Chem: 1 of its 10 programs at phase 2

  1. LG00313112phase 2
10%
22%
Phase 3

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%

LG Chem: 4 of its 10 programs at phase 3

  1. rilogrotugphase 3
  2. LBVDphase 3
  3. Metforminphase 3
  4. dapagliflozinphase 3
40%

Merck: 36 of its 85 programs at phase 3

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. tulisokibartphase 3
  4. ifinatamab deruxtecanphase 3
  5. intismeran autogenephase 3

and 31 more — sign in to see them all

42%
Approved, new studies

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

LG Chem: 3 of its 10 programs at approved, new studies

  1. Fang Le Shu (Follitrope)approved, new study
  2. Leuprolideapproved, new study
  3. gemigliptinapproved, new study
30%

Merck: 3 of its 85 programs at approved, new studies

  1. pembrolizumabapproved, new study
  2. sotaterceptapproved, new study
  3. Metforminapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
LG Chem0 readouts · 0 phase 3············
Merck25 readouts · 6 phase 3

Merck, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. pembrolizumabapproved, new study · Nov 20 · NCT04634877

Merck, Dec ’26: 3 programs whose next study reaches primary completion

  1. enlicitide chloridephase 3 · Dec 14 · NCT07776665
  2. F-2phase 1 · Dec 15 · NCT07748351
  3. efitazanamivir alfaphase 3 · Dec 31 · NCT07300085

Merck, Jan ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. remigromigphase 3 · Jan 11 · NCT06957080
  2. Human Papillomavirus Recombinant Vaccine nonavalentphase 3 · Jan 15 · NCT04199689
  3. alimatravirphase 3 · Jan 19 · NCT07600775

Merck, Feb ’27: 4 programs whose next study reaches primary completion

  1. nemtabrutinibphase 3 · Feb 1 · NCT07734610
  2. MK-6916phase 2 · Feb 9 · NCT07862621
  3. tulisokibartphase 3 · Feb 17 · NCT07486960
  4. belzutifanphase 3 · Feb 26 · NCT03634540

Merck, Mar ’27: 1 program whose next study reaches primary completion

  1. ensifentrinephase 3 · Mar 1 · NCT05270525

Merck, Apr ’27: 3 programs whose next study reaches primary completion

  1. MK-7602phase 1 · Apr 5 · NCT07919028
  2. pyronaridinephase 1 · Apr 5 · NCT07919028
  3. intismeran autogenephase 3 · Apr 23 · NCT06305767

Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sacituzumab tirumotecanphase 3 · May 10 · NCT06074588

Merck, Jun ’27: 2 programs whose next study reaches primary completion

  1. ifinatamab deruxtecanphase 3 · Jun 12 · NCT07405151
  2. ulonivirinephase 3 · Jun 29 · NCT05093972

Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. V118Ephase 1 · Jul 6 · NCT07168915
  2. bomedemstatphase 3 · Jul 14 · NCT06079879
  3. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Jul 30 · NCT07222488

Merck, Aug ’27: 1 program whose next study reaches primary completion

  1. islatravirphase 3 · Aug 10 · NCT06891066

Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zilovertamab vedotinphase 3 · Sep 24 · NCT05139017

Merck, Oct ’27: 2 programs whose next study reaches primary completion

  1. HRS-5346phase 2 · Oct 12 · NCT07614984
  2. MK-8690phase 2 · Oct 19 · NCT07895524
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 6

LG Chem

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 1

Merck

New programs 7

  • V951Aphase 1 · first study · Nov 10
  • pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
  • MK-2750phase 2 · first study · Oct 9 · Neoplasms
  • MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
  • V175phase 1 · first study · Sep 28
  • V175Aphase 1 · first study · Sep 28
  • Merck: new programs in 90 days

    1. V951Aphase 1 · first study · Nov 10
    2. pyronaridinephase 1 · first study · Oct 30
    3. MK-2750phase 2 · first study · Oct 9
    4. MK-6255phase 1 · first study · Oct 6
    5. V175phase 1 · first study · Sep 28

    and 2 more — sign in to see them all

Reached a new phase 2

  • gocatamigphase 3 · Oct 26 · Small Cell Lung Carcinoma
  • MK-6916phase 2 · Oct 2 · Renal Insufficiency

Study stopped 4

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 49 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionPfizerLG ChemMerck
Renal Insufficiencyall three · compare here

Pfizer in Renal Insufficiency: 4 programs

  1. prifetrastatphase 3
  2. abrocitinibphase 3
  3. osivelotorphase 3
  4. PF-07328948phase 2

Their studies: Pfizer’s studies of Renal Insufficiency in search

LG Chem in Renal Insufficiency: 1 program

  1. gemigliptinapproved, new study

Their studies: LG Chem’s studies of Renal Insufficiency in search

Merck in Renal Insufficiency: 7 programs

  1. calderasibphase 3
  2. nemtabrutinibphase 3
  3. alimatravirphase 3
  4. enlicitide chloridephase 3
  5. doravirinephase 3

and 2 more — sign in to see them all

Their studies: Merck’s studies of Renal Insufficiency in search

Breast Neoplasmsall three · compare here

Pfizer in Breast Neoplasms: 7 programs

  1. atirmociclibphase 3
  2. vepdegestrantphase 3
  3. prifetrastatphase 3
  4. disitamab vedotinphase 3
  5. tegtociclibphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Breast Neoplasms in search

LG Chem in Breast Neoplasms: 1 program

  1. Leuprolideapproved, new study

Their studies: LG Chem’s studies of Breast Neoplasms in search

Merck in Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Merck’s studies of Breast Neoplasms in search

Obesityall three · compare here

Pfizer in Obesity: 7 programs

  1. berobenatidephase 3
  2. PF-08653945phase 2
  3. danuglipronphase 2
  4. PF-07976016phase 2
  5. MET233phase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Obesity in search

LG Chem in Obesity: 1 program

  1. Metforminphase 3

Their studies: LG Chem’s studies of Obesity in search

Merck in Obesity: 3 programs

  1. efinopegdutidephase 2
  2. TERN-601phase 2
  3. Metforminapproved, new study

Their studies: Merck’s studies of Obesity in search

Diabetes Mellitus, Type 2all three · compare here

Pfizer in Diabetes Mellitus, Type 2: 2 programs

  1. berobenatidephase 3
  2. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus, Type 2 in search

LG Chem in Diabetes Mellitus, Type 2: 3 programs

  1. Metforminphase 3
  2. dapagliflozinphase 3
  3. gemigliptinapproved, new study

Their studies: LG Chem’s studies of Diabetes Mellitus, Type 2 in search

Merck in Diabetes Mellitus, Type 2: 4 programs

  1. efinopegdutidephase 2
  2. MK-1403phase 1
  3. MK-2828phase 1
  4. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus, Type 2 in search

Ovarian Neoplasmsall three · compare here

Pfizer in Ovarian Neoplasms: 1 program

  1. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Ovarian Neoplasms in search

LG Chem in Ovarian Neoplasms: 1 program

  1. LG00313112phase 2

Their studies: LG Chem’s studies of Ovarian Neoplasms in search

Alzheimer Diseaseall three · compare here

Pfizer in Alzheimer Disease: 1 program

  1. PF-08161842phase 1

Their studies: Pfizer’s studies of Alzheimer Disease in search

LG Chem in Alzheimer Disease: 1 program

  1. Leuprolideapproved, new study

Their studies: LG Chem’s studies of Alzheimer Disease in search

Merck in Alzheimer Disease: 3 programs

  1. MK-2214phase 2
  2. BCG Vaccinephase 2
  3. MK-1167phase 2

Their studies: Merck’s studies of Alzheimer Disease in search

Diabetes Mellitusall three · compare here

Pfizer in Diabetes Mellitus: 1 program

  1. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus in search

LG Chem in Diabetes Mellitus: 2 programs

  1. Metforminphase 3
  2. dapagliflozinphase 3

Their studies: LG Chem’s studies of Diabetes Mellitus in search

Merck in Diabetes Mellitus: 1 program

  1. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus in search

Prostatic Neoplasmsall three · compare here

Pfizer in Prostatic Neoplasms: 1 program

  1. mevrometostatphase 3

Their studies: Pfizer’s studies of Prostatic Neoplasms in search

LG Chem in Prostatic Neoplasms: 1 program

  1. Leuprolideapproved, new study

Their studies: LG Chem’s studies of Prostatic Neoplasms in search

Merck in Prostatic Neoplasms: 1 program

  1. opevesostatphase 3

Their studies: Merck’s studies of Prostatic Neoplasms in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

Pfizer in Carcinoma, Non-Small-Cell Lung: 9 programs

  1. tivunatamigphase 3
  2. prifetrastatphase 3
  3. disitamab vedotinphase 3
  4. sigvotatug vedotinphase 3
  5. ponsegromabphase 3

and 4 more — sign in to see them all

Their studies: Pfizer’s studies of Carcinoma, Non-Small-Cell Lung in search

–

Merck in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. sacituzumab tirumotecanphase 3
  2. ifinatamab deruxtecanphase 3
  3. intismeran autogenephase 3
  4. patritumab deruxtecanphase 3
  5. calderasibphase 3

and 6 more — sign in to see them all

Their studies: Merck’s studies of Carcinoma, Non-Small-Cell Lung in search

Neoplasms2 of 3 · compare here

Pfizer in Neoplasms: 1 program

  1. tucatinibapproved, new study

Their studies: Pfizer’s studies of Neoplasms in search

–

Merck in Neoplasms: 14 programs

  1. belzutifanphase 3
  2. ifinatamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. calderasibphase 3
  5. opevesostatphase 3

and 9 more — sign in to see them all

Their studies: Merck’s studies of Neoplasms in search

Dermatitis, Atopic2 of 3 · compare here

Pfizer in Dermatitis, Atopic: 7 programs

  1. tilrekimigphase 3
  2. abrocitinibphase 3
  3. etrasimodphase 3
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Dermatitis, Atopic in search

–

Merck in Dermatitis, Atopic: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Dermatitis, Atopic in search

Melanoma2 of 3 · compare here–

Merck in Melanoma: 4 programs

  1. intismeran autogenephase 3
  2. patritumab deruxtecanphase 3
  3. BCG Vaccinephase 2
  4. pembrolizumabapproved, new study

Their studies: Merck’s studies of Melanoma in search

Show all 49

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetPfizerLG ChemMerck
GLP1Rberobenatide, PF-08642534, PF-08656795, danuglipronrule–efinopegdutide
PDCD1sasanlimab, tivunatamig–Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010, pembrolizumabrule, pembrolizumab, berahyaluronidase alfa drug combinationrule
CD3Eelranatamabrule–Anti-CD19/CD3 Bispecific Antibody MK-1045, gocatamig
BTKritlecitinibrule–nemtabrutinib
COXFA4–MetforminruleMetforminrule
COXFA4L2–MetforminruleMetforminrule
GDF15ponsegromabrilogrotugrule–
GPD2–MetforminruleMetforminrule
KRASPan-KRAS Inhibitor PF-07985045rule–calderasib
MT-ND1–MetforminruleMetforminrule
MT-ND2–MetforminruleMetforminrule
MT-ND3–MetforminruleMetforminrule
MT-ND4–MetforminruleMetforminrule
MT-ND4L–MetforminruleMetforminrule
MT-ND5–MetforminruleMetforminrule
MT-ND6–MetforminruleMetforminrule
NDUFA1–MetforminruleMetforminrule
NDUFA10–MetforminruleMetforminrule
NDUFA11–MetforminruleMetforminrule
NDUFA12–MetforminruleMetforminrule
NDUFA13–MetforminruleMetforminrule
NDUFA2–MetforminruleMetforminrule
NDUFA3–MetforminruleMetforminrule
NDUFA5–MetforminruleMetforminrule
NDUFA6–MetforminruleMetforminrule
NDUFA7–MetforminruleMetforminrule
NDUFA8–MetforminruleMetforminrule
NDUFA9–MetforminruleMetforminrule
NDUFAB1–MetforminruleMetforminrule
NDUFAF1–MetforminruleMetforminrule
NDUFAF2–MetforminruleMetforminrule
NDUFAF3–MetforminruleMetforminrule
NDUFAF4–MetforminruleMetforminrule
NDUFB1–MetforminruleMetforminrule
NDUFB10–MetforminruleMetforminrule
NDUFB11–MetforminruleMetforminrule
NDUFB2–MetforminruleMetforminrule
NDUFB3–MetforminruleMetforminrule
NDUFB4–MetforminruleMetforminrule
NDUFB5–MetforminruleMetforminrule
NDUFB6–MetforminruleMetforminrule
NDUFB7–MetforminruleMetforminrule
NDUFB8–MetforminruleMetforminrule
NDUFB9–MetforminruleMetforminrule
NDUFC1–MetforminruleMetforminrule
NDUFC2–MetforminruleMetforminrule
NDUFS1–MetforminruleMetforminrule
NDUFS2–MetforminruleMetforminrule
NDUFS3–MetforminruleMetforminrule
NDUFS4–MetforminruleMetforminrule
NDUFS5–MetforminruleMetforminrule
NDUFS6–MetforminruleMetforminrule
NDUFS7–MetforminruleMetforminrule
NDUFS8–MetforminruleMetforminrule
NDUFV1–MetforminruleMetforminrule
NDUFV2–MetforminruleMetforminrule
NDUFV3–MetforminruleMetforminrule
VEGFAtivunatamig–Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010
A target, or a pathogen for a vaccine, known for: Pfizer 67 of 91 · LG Chem 5 of 10 · Merck 41 of 85 programs (35 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Pfizer: 9).